Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Gynecology

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 48 articles: HTML format

Single Articles

May 2025
1. WEHBE S, Gallwas J, Grundker C
   Inhibition of Plasminogen Activator Inhibitor-1 (PAI-1) by Tiplaxtinin Reduces Aggressiveness of Cervical Carcinoma Cells.
   Anticancer Res. 2025;45:1793-1805.
   PubMed     Abstract available
   
   
   
2. BAL J, Fulawka L, Gabrys M, Murawski M, et al
   Potential Role of PTEN and AKT/PKB Proteins in the Pathogenesis of Ovarian Mature Teratomas.
   Anticancer Res. 2025;45:1843-1851.
   PubMed     Abstract available
   
   
   
3. SIMONETTI E, Pistolesi S, Ferrari A, Della Rosa M, et al
   Role of Stromal CD25+/CD8+ Lymphocyte Ratio in Patients With Grade 2-3 Cervical Intraepithelial Neoplasia (CIN 2-3): A Retrospective Single-center Study.
   Anticancer Res. 2025;45:2041-2050.
   PubMed     Abstract available
   
   
   
4. TSUKAMOTO YO, Ohtsuka T, Yamauchi Y, Mun M, et al
   Efficacy and Prognostic Factors of Surgical Resection for Pulmonary Metastases From Ovarian Cancer.
   Anticancer Res. 2025;45:2071-2078.
   PubMed     Abstract available
   
   
   April 2025
5. DAMPALI R, Nikolettos K, Psilopatis I, Kostaki EG, et al
   The Impact of Body Mass Index on Sentinel Lymph Node Identification in Endometrial Cancer.
   Anticancer Res. 2025;45:1575-1581.
   PubMed     Abstract available
   
   
   March 2025
6. WU YC, Ku MH, Huang WL, Dias L, et al
   NEAT1 in Ovarian Cancer: A Key Regulator of Tumor Progression, Follicular Fluid Dynamics, and Therapeutic Resistance.
   Anticancer Res. 2025;45:825-842.
   PubMed     Abstract available
   
   
   
7. AHMADU T, Olawade DB, Teke J, Bachour ME, et al
   Diagnosis and Treatment of Gestational Non-Epithelial Ovarian Cancer: A Systematic Review.
   Anticancer Res. 2025;45:843-853.
   PubMed     Abstract available
   
   
   
8. KOH JW, Park SJ
   Knockdown of RFC2 Prevents the Proliferation, Migration and Invasion of Cervical Cancer Cells.
   Anticancer Res. 2025;45:989-1000.
   PubMed     Abstract available
   
   
   February 2025
9. STUEBS FA, Dietl AK, Schulmeyer CE, Behrens AS, et al
   Prognostic Significance of the Detection of Human Papilloma Virus L1 Protein in Smears of Cervical Intraepithelial Neoplasia Grade 3 in Pregnant Women.
   Anticancer Res. 2025;45:677-683.
   PubMed     Abstract available
   
   
   
10. SANTANA BN, Arencibia O, Babin G, Tommasetti E, et al
    Use of Indocyanine Green Fluorescence Angiography to Assess Bowel Anastomosis in Ovarian Cancer Surgery.
    Anticancer Res. 2025;45:661-666.
    PubMed     Abstract available
    
    
    
11. SHIEH PC, Shih HY, Chuang CL, Tsai CW, et al
    Association of Matrix Metalloproteinase-1 Promoter Genotypes With Endometriosis Risk.
    Anticancer Res. 2025;45:465-471.
    PubMed     Abstract available
    
    
    January 2025
12. TALIJANOVIC M, Lopacinska-Jorgensen J, Hogdall EV
    Gene Expression Profiles in Ovarian Cancer Tissues as a Potential Tool to Predict Platinum-based Chemotherapy Resistance.
    Anticancer Res. 2025;45:11-26.
    PubMed     Abstract available
    
    
    
13. KARSTENSEN S, Kaiser K, Poulsen TS, Jochumsen K, et al
    Ovarian Adult Granulosa Cell Tumors: A Scoping Review of DNA Alterations and Their Known Significance.
    Anticancer Res. 2025;45:1-10.
    PubMed     Abstract available
    
    
    
14. LINDQVIST PG, Gissler M
    Improved Vitamin D Status Is Associated With Lower Incidence of Stillbirth.
    Anticancer Res. 2025;45:243-250.
    PubMed     Abstract available
    
    
    December 2024
15. KONTOMANOLIS E, Koutras A, Mitrakas AG, Trypsianis G, et al
    Tissue Expression and Plasma Soluble PD-L1 Levels in Patients With Endometrial Cancer.
    Anticancer Res. 2024;44:5525-5530.
    PubMed     Abstract available
    
    
    
16. ULKER EB, Aktas EC, Seyhan MF, Isbir T, et al
    Effects of Curcumin and Its Analogue Desmethoxycurcumin on miR-133b and Its Target Gene GSTP-1 in Cisplatin-resistant Ovarian Cancer Cells.
    Anticancer Res. 2024;44:5351-5359.
    PubMed     Abstract available
    
    
    
17. CHO Y, Kim HS
    Immunohistochemical Expression and Significance of Preferentially Expressed Antigen in Melanoma (PRAME) in Gynecological Tumors: A Single-institution Retrospective Analysis.
    Anticancer Res. 2024;44:5515-5524.
    PubMed     Abstract available
    
    
    November 2024
18. LENZ C, Gesemann L, Al-Baldawi Y, Pusken M, et al
    Accuracy of Preoperative Magnet Resonance Imaging to Predict Pathologic T-Stage in Patients With Cervical Cancer.
    Anticancer Res. 2024;44:5081-5085.
    PubMed     Abstract available
    
    
    
19. NA JM, Kim HS
    Comprehensive Clinicopathological and Immunohistochemical Analysis of Human Papillomavirus-independent Squamous Cell Carcinoma and Adenosquamous Carcinoma of the Uterine Cervix.
    Anticancer Res. 2024;44:4969-4981.
    PubMed     Abstract available
    
    
    
20. COCCHI S, Lopacinska-Jorgensen J, Hogdall EV
    Potential Transcriptomic Biomarkers for Predicting Platinum-based Chemotherapy Resistance in Patients With High-grade Serous Ovarian Cancer.
    Anticancer Res. 2024;44:4691-4707.
    PubMed     Abstract available
    
    
    
21. LEE HM, Cho HJ, Lee YM, Kim HJ, et al
    Fostamatinib Inhibits the Proliferation of Ovarian Cancer Cells Through Apoptosis Induction.
    Anticancer Res. 2024;44:4895-4903.
    PubMed     Abstract available
    
    
    
22. SIN J, Kiosea M, Mahdavi K, Akbarpour F, et al
    Investigation of the Efficacy of Nowarta110 in the Treatment of HPV-16 and HPV-18 Oncogenically-transformed Human Cells and Cancer-implanted Animal Models.
    Anticancer Res. 2024;44:4723-4728.
    PubMed     Abstract available
    
    
    
23. LEE J, Chi SA, Choi S, Kim HS, et al
    Invasive Stratified Mucin-producing Carcinoma of the Uterine Cervix: Comparison of Its Clinicopathological Characteristics and Programmed Death-ligand 1 Expression Status With Those of Other Endocervical Adenocarcinomas.
    Anticancer Res. 2024;44:5007-5022.
    PubMed     Abstract available
    
    
    October 2024
24. SANTANA BN, Guyon F, Arencibia O, Babin G, et al
    Factors Limiting Ostomy Reversal After Cytoreductive Surgery for Ovarian Cancer: A Retrospective Study.
    Anticancer Res. 2024;44:4413-4418.
    PubMed     Abstract available
    
    
    
25. LEE J, Heo K
    Repurposing Valrubicin as a Potent Inhibitor of Ovarian Cancer Cell Growth.
    Anticancer Res. 2024;44:4301-4307.
    PubMed     Abstract available
    
    
    
26. HA H, Ryu JY, Yoon S, Cho YJ, et al
    Anticancer Effects of BAF312 (Siponimod) in Epithelial Ovarian Cancer.
    Anticancer Res. 2024;44:4273-4282.
    PubMed     Abstract available
    
    
    September 2024
27. SMOLARZ B, Lukasiewicz H, Samulak D, Kolacinski R, et al
    Hypoxia-induced Factor-1alpha and its Role in Endometrial Cancer.
    Anticancer Res. 2024;44:3697-3712.
    PubMed     Abstract available
    
    
    August 2024
28. KYRIAZOGLOU A, Papachristou DJ, Moutafi M, Papakosta A, et al
    Implications of the Hippo Pathway Dysregulation in Uterine Leiomyosarcoma.
    Anticancer Res. 2024;44:3331-3336.
    PubMed     Abstract available
    
    
    
29. HIRAKAWA T, Yotsumoto F, Imi S, Ito N, et al
    Adipose-derived Mesenchymal Stem Cell Transplantation Improves Ovarian Function and Oocyte Quality in Aged Mice.
    Anticancer Res. 2024;44:3577-3586.
    PubMed     Abstract available
    
    
    July 2024
30. LI Q, Guan T, Mao J, King BP, et al
    Mast Cell-related Prognosis Signature Characterizes Immune Landscape and Predicts Prognosis of Ovarian Cancer.
    Anticancer Res. 2024;44:2775-2786.
    PubMed     Abstract available
    
    
    
31. CHIEN HJ, Wang YC, Chang WS, Hsieh YH, et al
    Contribution of Matrix Metalloproteinase-7 Genotypes to Endometriosis Risk in Taiwan.
    Anticancer Res. 2024;44:3051-3058.
    PubMed     Abstract available
    
    
    
32. CHOI EY, Han EJ, Jeon SJ, Lee SW, et al
    Kaempferol Inhibits Cervical Cancer Cells by Inducing Apoptosis and Autophagy via Inactivation of the PI3K/AKT/mTOR Signaling Pathway.
    Anticancer Res. 2024;44:2961-2972.
    PubMed     Abstract available
    
    
    
33. MAFUNE S, Someya M, Hasegawa T, Tsuchiya T, et al
    Analysis of Treatment Response With Proteins Related to Tumor Immunity in Postoperative Irradiated Cervical Cancer Patients.
    Anticancer Res. 2024;44:3077-3086.
    PubMed     Abstract available
    
    
    
34. ZHANG Y, Niu X, Wang Y, Bao S, et al
    SIRT4 Has an Anti-Cancer Role in Cervical Cancer by Inhibiting Glutamine Metabolism via the MEK/ERK/C-Myc Axis.
    Anticancer Res. 2024;44:2861-2870.
    PubMed     Abstract available
    
    
    June 2024
35. LEONHARDI J, Horn LC, Aktas B, Denecke T, et al
    MRI Texture Analysis of Inguinal Lymph Node Metastasis in Vulvar Cancer - Associations With Histopathology.
    Anticancer Res. 2024;44:2709-2716.
    PubMed     Abstract available
    
    
    
36. MORGENSTERN B, Thangarajah F, Schmidt M, Lenz C, et al
    Clinical Impact of Pelvic Sentinel Lymph Node Biopsy for Vulvar Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:2621-2626.
    PubMed     Abstract available
    
    
    
37. KITSOS-KALYVIANAKIS K, Pitsikakis K, Mamalis ME, Kalampokis E, et al
    Continuity Unveiled: Evaluating Cytoreduction Outcomes for Advanced Ovarian Cancer Amidst the COVID-19 Era at an ESGO Designated Centre of Excellence.
    Anticancer Res. 2024;44:2645-2652.
    PubMed     Abstract available
    
    
    May 2024
38. YAMAOKA Y, Tamura S, Yamanoi K, Taki M, et al
    Clinical Significance of Serum SCC Levels Before Treatment for Locally Advanced Cervical Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:2009-2019.
    PubMed     Abstract available
    
    
    
39. JUNG BC, Woo SH, Kim SH, Kim YS, et al
    Parkin Enhances Gefitinib-induced Anoikis in HeLa Cervical Cancer Cells.
    Anticancer Res. 2024;44:1853-1862.
    PubMed     Abstract available
    
    
    
40. WILLSON CM, Lequio M, Zhu Z, Wakefield MR, et al
    The Role of SARS-CoV-2 Spike Protein in the Growth of Cervical Cancer Cells.
    Anticancer Res. 2024;44:1807-1815.
    PubMed     Abstract available
    
    
    
41. KUM SJ, Jung YY, Kim HS
    Comparison of Clinicopathological and Prognostic Characteristics Between Minimal Deviation Adenocarcinoma and Gastric-type Endocervical Adenocarcinoma.
    Anticancer Res. 2024;44:2193-2204.
    PubMed     Abstract available
    
    
    
42. MOREA A, Saravi S, Sisu C, Hall M, et al
    Effect of MYC and PARP Inhibitors in Ovarian Cancer Using an In Vitro Model.
    Anticancer Res. 2024;44:1817-1827.
    PubMed     Abstract available
    
    
    April 2024
43. XU X, Wang Q, Shen L, Shen Y, et al
    Anlotinib Inhibits Ovarian Cancer and Enhances Cisplatinum Sensitivity via Suppressing NOTCH2 Expression and Stemness.
    Anticancer Res. 2024;44:1399-1407.
    PubMed     Abstract available
    
    
    
44. TSENG CC, Ku MH, Wu YC, Huang WL, et al
    Therapeutic Options Targeting the Ataxia-Telangiectasia Mutated (ATM)-mediated DNA Damage Response, Macropinocytosis, and Adaptive Immunity in Ovarian Cancer.
    Anticancer Res. 2024;44:1353-1364.
    PubMed     Abstract available
    
    
    
45. CHU J, Lee SH, DO SI, Kim HS, et al
    Clinicopathological Significance of Nucleosome Remodeling and Deacetylase Complex Expression in Endometrial Carcinoma.
    Anticancer Res. 2024;44:1739-1750.
    PubMed     Abstract available
    
    
    
46. AOSHIKA T, Noda SE, Abe T, Kumazaki YU, et al
    Results of Definitive (Chemo)radiotherapy Using Computed Tomography-based Brachytherapy for Cervical Cancer.
    Anticancer Res. 2024;44:1583-1589.
    PubMed     Abstract available
    
    
    
47. WANG X, Li C, Lou L, Zhu H, et al
    Roles of Matrix Metalloproteinases 2 and 9 in Uterine Leiomyosarcoma.
    Anticancer Res. 2024;44:1465-1473.
    PubMed     Abstract available
    
    
    March 2024
48. KIM JS, Shin MJ, Lee SY, Choi SM, et al
    BBT-877, a Novel Autotaxin Inhibitor, Abrogates Drug Resistance in Epithelial Ovarian Cancer Stem Cells.
    Anticancer Res. 2024;44:1131-1142.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.